Emerging clinical issues and multivariate analyses in PET investigations

Area of Science:

• Neurology
• Nuclear Medicine
• Radiology

Background:

• 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) is increasingly used in diagnosing common neurodegenerative diseases.
• FDG-PET imaging offers valuable diagnostic information for rarer neurological conditions, crucial for timely patient management.
• Emerging applications of FDG-PET are significant in prion diseases, autoimmune encephalitis (AE), and amyotrophic lateral sclerosis (ALS).

Purpose of the Study:

• To review the emerging diagnostic utility of FDG-PET in specific neurological disorders.
• To highlight FDG-PET's ability to detect early metabolic changes, sometimes preceding other imaging findings.
• To discuss the role of FDG-PET in differential diagnosis for challenging neurological cases.

Main Methods:

• Review of current literature on FDG-PET applications in prion diseases, AE, and ALS.
• Analysis of characteristic FDG-PET findings in these conditions, including hypometabolism and hypermetabolism patterns.
• Discussion of advanced analytical techniques for PET image analysis, such as multivariate and component analyses.

Main Results:

• FDG-PET can detect early-stage metabolic abnormalities in prion diseases, AE, and ALS, even with normal MRI.
• Specific patterns like thalamic hypometabolism are noted in Creutzfeldt-Jacob disease and fatal familial insomnia.
• FDG-PET aids in differentiating ALS subtypes and predicting progression to frontotemporal dementia.

Conclusions:

• FDG-PET is a valuable tool for early and accurate diagnosis of less common neurological disorders.
• Its ability to reveal subtle metabolic changes enhances diagnostic sensitivity beyond standard biomarkers.
• Advanced PET image analysis improves the discrimination accuracy for these complex neurological conditions.